This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL). Acalabrutinib (ACP-196) is a next generation bruton tyrosine kinase (BTK) inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab. In this trial proposal, we will also assess the activity of this combination in comparison to a historical control of ibrutinib + rituximab, consisting of the experimental arm of ibrutinib + rituximab in the randomized ENRICH trial (EudraCT number 2015-000832-13), and data from our previous trial with R-bendamustine-lenalidomide (NLG-MCL4). The duration of treatment will be a minimum of 12 months. Patients in molecular remission in blood and bone marrow and in complete remission according to CT, will then stop acalabrutinib, but continue on rituximab for a maximum of 36 months. Patients that are minimal residual disease positive (MRD+) will be evaluated again every 6 months and continue on acalabrutinib for a maximum of 36 months. Patients without a molecular marker, that cannot be followed with MRD, will stop treatment if in CR with PET at 12 months, and be followed by PET-CT every 6 months for a maximum of 36 months. Patients who convert back to MRD positive after stopping acalabrutinib are reinstalled on acalabrutinib until progression. Patients with TP53 aberrations and/or blastoid histology, will monitor MRD but continue with treatment until progression regardless of MRD results. A planned interim analysis will be performed when 40 patients have undergone response assessment after 6 months, for futility and efficacy. If less than 16 of 40 patients obtain a CR, the trial will be stopped due to futility.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
81
Acalabrutinib, or ACP-196, is a next generation BTK inhibitor, more selective than ibrutinib, and without in vitro antagonism of anti-CD20 directed immunotherapies, indicating that its combination with rituximab may be more active than the combination of ibrutinib and rituximab
Department of Hematology X, Odense University Hospital
Odense, Denmark
Department of Hematology, Zeeland University Hospital Roskilde
Roskilde, Denmark
Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center
Helsinki, Finland
Oulu University Hospital
Oulu, Finland
Department of Oncology, Haukeland University Hospital
Bergen, Norway
Avd. for Kreftbehandling, Oslo Universitetssykehus
Oslo, Norway
Avdeling for Blod- og Kreftsykdommer, Stavanger Universitetssykehus
Stavanger, Norway
Kreftklinikken, St Olavs Hospital
Trondheim, Norway
Division of Hematology-Oncology Samsung Medical Center Seoul
Seoul, South Korea
Hematological Department, Falu Hospital, Falun
Falun, Sweden
...and 10 more locations
Progression-free survival
The primary efficacy endpoint is progression-free survival, compared to the MCL4 data by log rank test
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.